#USA #New York #Class Action #Pomerantz Law Firm #3D Systems

Pomerantz Law Firm Sues 3D Systems Corporation

On July 17, 2025, Pomerantz LLP announced the initiation of a class action lawsuit against 3D Systems Corporation, a well-known entity in the additive manufacturing sector, alongside some of its key executives. The lawsuit was filed in the United States District Court for the District of Delaware, and it pertains to all individuals and entities that bought or acquired securities of 3D Systems between August 13, 2024, and May 12, 2025 (known as the "Class Period"). The suit aims to recover losses stemming from the alleged violations of federal securities laws under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5.

For investors looking to join the class, they must request to be appointed as Lead Plaintiff by August 12, 2025. More details can be found at Pomerantz Law's website.

3D Systems operates within the healthcare and industrial segments, providing innovative 3D printing solutions across various regions, including North America, Europe, and Asia. Their Healthcare Solutions segment encompasses essential domains such as dental implants and regenerative medicine, where they have been working on a transformative project aimed at 3D printing human organs, specifically targeting lung transplants for patients suffering from end-stage lung disease.

However, as the company pushed forward with this ambitious project, they faced significant challenges. The class action lawsuit alleges that 3D Systems understated the adverse impact of declining customer spending on its financial well-being. During the Class Period, the firm is alleged to have misrepresented its financial health and overstated its capacity to navigate tough market conditions.

In a concerning trend, reports indicated that the company's revenue dropped dramatically, alongside a notable decline in stock value. For instance, a March 2025 press release highlighted their fourth-quarter results where they declared a notable drop in sales that contradicted investors’ expectations, leading to a decline of over 20% in their stock value soon after. Pomerantz's complaint indicates that 3D Systems failed to disclose the redefined milestone criteria for the Regenerative Medicine Program, which they believe also adversely affected revenue prospects.

Another troubling report highlighted a significant loss in adjusted earnings and a drop in sales revenue compared to the previous year, prompting a decision to withdraw the company’s full-year guidance for 2025 amid uncertainties in customer spending patterns. Such missteps compelled analysts to express skepticism regarding the company's ability to return to profitability.

Founded by the renowned Abraham L. Pomerantz, Pomerantz LLP is considered a leader in securities class action litigation. With over 85 years in operation, they continue to advocate for victims of corporate misconduct and securities fraud. The firm has successfully recovered substantial settlements for class members in prior actions and maintains a dedicated approach in pursuing justice for their clients.

Investors with concerns regarding their securities investments in 3D Systems during the announced Class Period should consider reaching out to Pomerantz LLP for guidance. The firm is known for its commitment to upholding investor rights, and this action is a testament to their ongoing effort to hold corporations accountable for their actions and communications.

For further inquiries, potential class members can contact Danielle Peyton at Pomerantz LLP via email or phone, and they are encouraged to provide their contact information and specifics about their investment history.

In summary, as the class action against 3D Systems unfolds, it highlights not just the challenges faced by one company in a competitive market, but also the broader implications for investors as they navigate the complexities of corporate disclosures and market reactions.